View Older Stories View More Recent Stories

Jul 13, 2026 06:00AM Agenus raises up to $340M to fund MSS colon cancer Phase 3 trial
Jul 13, 2026 06:00AM Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
Jul 7, 2026 04:42PM Form SCHEDULE 13D/A Climb Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Jul 7, 2026 04:01PM Vor Bio names David Zaccardelli to its board of directors
Jul 7, 2026 04:01PM Vor Bio Appoints David Zaccardelli to Board of Directors
Jul 2, 2026 08:27PM Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jul 2, 2026 02:01AM Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Jul 2, 2026 02:01AM PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Jun 29, 2026 07:02AM Talawar Therapeutics to go public via SPAC deal with $225M PIPE
Jun 29, 2026 07:00AM Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics f
Jun 26, 2026 05:39PM Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 25, 2026 08:15AM NIMA and RA Capital Launch First-of-Its-Kind Workplace Pilot to Support Employees with Celiac Disease
Jun 24, 2026 08:00PM Ollin Biosciences raises $330M Series B to fund eye disease trials
Jun 24, 2026 08:00PM Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second
Jun 24, 2026 06:49PM Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 24, 2026 07:01AM Ollin Biosciences raises $330M Series B for eye disease drug trials
Jun 24, 2026 07:00AM Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026
Jun 23, 2026 11:11AM These Emerging Companies Are Racing Toward Major Catalysts
Jun 23, 2026 09:00AM NorthLinks Bio Launches with $34 Million Financing to Advance Broad-Spectrum Respiratory Antiviral Platform
Jun 23, 2026 07:30AM Boundless Bio agrees to merge with Serapha Bio in all-stock deal
Jun 23, 2026 07:30AM Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
Jun 22, 2026 07:02PM Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 18, 2026 04:10PM Form SCHEDULE 13D Parabilis Medicines, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 18, 2026 04:01PM Memento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal Diseases 
Jun 15, 2026 08:16PM Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 15, 2026 07:37PM Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 9, 2026 07:00AM Atavistik Bio Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ATV-1601 for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
Jun 4, 2026 05:01PM Form SCHEDULE 13G Q32 Bio Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 3, 2026 04:46PM Form SCHEDULE 13G Editas Medicine, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 2, 2026 08:00AM Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development
May 27, 2026 12:29PM Secretome Therapeutics Announces $30 Million Series A Financing From RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy
May 27, 2026 08:41AM Q32 Bio shares up 26% on $55 million financing round
May 27, 2026 08:00AM Q32 Bio raises $55 million in private placement financing
May 27, 2026 08:00AM Q32 Bio Announces $55 Million Private Placement Financing
May 21, 2026 09:13PM Form SCHEDULE 13G Sana Biotechnology, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 20, 2026 09:28AM Radence Opens Flagship Precision Health Hub in West Palm Beach, Introducing a Private Setting for Personalized Preventive Care
May 20, 2026 09:00AM Research Alliance Corporation III prices $75 million IPO at $10 per share
May 20, 2026 09:00AM RESEARCH ALLIANCE CORPORATION III ANNOUNCES PRICING OF $75 MILLION INITIAL PUBLIC OFFERING
May 15, 2026 04:51PM Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:49PM Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:47PM Form SCHEDULE 13G/A Invivyd, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:47PM Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:46PM Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:44PM Form SCHEDULE 13G/A Contineum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:43PM Form SCHEDULE 13G/A Avidity Biosciences, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:42PM Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:41PM Form SCHEDULE 13G Atrium Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:36PM Form SCHEDULE 13G/A 4D Molecular Therapeutic Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:34PM Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
May 15, 2026 09:00AM Sana Biotechnology raises $69 million through share sale
View More Recent Stories View Older Stories